February 21,
2019
Ultragenyx Announces Positive 24-week Data from First Cohort of Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia
February 19,
2019
Ultragenyx Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Update
February 14,
2019
Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita® (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH)